Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy.
Bo Liu, Yao Bao, Jinan Ma, Xiaodong Wang, Yeqian Feng · Advances in radiation oncology · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont, no significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. No significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT.
What the Researchers Studied
The researchers studied participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
66.6% inhaled H₂ concentration. No significant difference in tumor response was observed between groups based on the Response Evaluation Criteria in Solid Tumors, suggesting that hydrogen therapy did not interfere with the antitumor efficacy of CCRT. The authors concluded that hydrogen inhalation is a safe and effective adjunctive therapy that significantly alleviates inflammation and mitigates clinical symptoms of ARE in patients with cervical cancer who are undergoing CCRT, without compromising antitumor treatment outcomes. Molecular hydrogen, as a novel antioxidant and anti-inflammatory agent, may alleviate treatment-related toxicity.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was participants with cervical cancer undergoing CCRT were prospectively enrolled and randomized into an experimental group (n = 28) or a cont. The study used a randomized human clinical trial. The reported hydrogen concentration was 66.6% inhaled H₂ concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.